

Special Issue

Personalized Diagnosis and Treatment of Breast Cancer

Message from the Guest Editors

Breast cancer is one of the most frequent cancers among women and is found to be highly heterogeneous. Importantly, overall survival has improved, mainly due to better medical care, early detection, and important progress of treatments. Although the 5-year overall survival rate of early breast cancer is over 90%, many patients still undergo recurrence, metastasis and drug resistance, even after standard treatment in clinical practice, besides treating breast cancer based on molecular subtypes. This Special Issue of *Journal of Personalized Medicine* is focused on addressing the latest research on the diagnosis of breast cancer, including prevention, onset, and progression, as well as the potential of personalized therapies at different levels, with special attention to immunotherapy, targeted therapies, chemo and radiation therapy, and surgery, as well as resistance to treatment to improve patient prognosis.

Guest Editors

Dr. Amabile Maria Ida

Department of Surgical Sciences, Sapienza University of Rome, Rome, Italy

Dr. Salvatore Sorrenti

Department of Surgical Sciences, Sapienza University of Rome, 00161 Rome, Italy

Deadline for manuscript submissions

closed (25 July 2023)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/85906

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).